Cidara Therapeutics (CDTX) to Release Earnings on Thursday

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect Cidara Therapeutics to post earnings of ($5.45) per share for the quarter.

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) EPS for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%. On average, analysts expect Cidara Therapeutics to post $-9 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Cidara Therapeutics Price Performance

Cidara Therapeutics stock opened at $20.89 on Thursday. The firm has a market capitalization of $228.81 million, a P/E ratio of -0.82 and a beta of 0.89. The company's 50-day moving average is $20.92 and its 200 day moving average is $19.85. Cidara Therapeutics has a 1-year low of $10.14 and a 1-year high of $28.42.

Insiders Place Their Bets

In related news, insider Leslie Tari sold 1,773 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total value of $38,935.08. Following the transaction, the insider now owns 16,215 shares of the company's stock, valued at approximately $356,081.40. This trade represents a 9.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Shane Ward sold 1,664 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total transaction of $36,541.44. Following the completion of the transaction, the chief operating officer now directly owns 14,674 shares of the company's stock, valued at approximately $322,241.04. The trade was a 10.18 % decrease in their position. The disclosure for this sale can be found here. 7.64% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. HC Wainwright lifted their price objective on Cidara Therapeutics from $24.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Needham & Company LLC restated a "buy" rating and set a $35.00 target price on shares of Cidara Therapeutics in a research report on Thursday, April 10th. JMP Securities reissued a "market outperform" rating and set a $46.00 price objective on shares of Cidara Therapeutics in a research note on Tuesday. Cantor Fitzgerald raised shares of Cidara Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 5th. Finally, Citigroup began coverage on shares of Cidara Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Cidara Therapeutics has a consensus rating of "Buy" and a consensus target price of $39.14.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.